. The chemist and druggist [electronic resource] . having to repeat all the previous workconvincing patients that it is only achange of name but now with theadded bonus of far more patients andtheir greater awareness of theBecotide and Ventolin brands. Butworse was to come because, as thename once again changed, came thedreaded tale from the wholesaler ofsorry manufacturer cannot supply. I have now had no supplies ofEasibreathe inhalers for three commercial agreements that existbetween Glaxo Wellcome and Nortonmay be theirs alone but they also havea wider responsibility to theircusto
. The chemist and druggist [electronic resource] . having to repeat all the previous workconvincing patients that it is only achange of name but now with theadded bonus of far more patients andtheir greater awareness of theBecotide and Ventolin brands. Butworse was to come because, as thename once again changed, came thedreaded tale from the wholesaler ofsorry manufacturer cannot supply. I have now had no supplies ofEasibreathe inhalers for three commercial agreements that existbetween Glaxo Wellcome and Nortonmay be theirs alone but they also havea wider responsibility to theircustomers and mine. 1 have ordered more Easibreatheson back order but I have had nodelivery date, explanation for theproblem or even an apology to passon to my patients. Meanwhile existingpatients have had to revert to anordinary inhaler or use the alternativeAutohaler least 3Mhave not complained! No relaxationof protocols withLevonelle-2 Most medicines are marketed to aprice formula that only and the OFT find unacceptable. but with the imminent launch ofLevonelle-2 at £ (why not ±20 toreflect a true professional product)my £10 profit fee has beenquestioned in the media amidaccusations of profiteering (C&D 30December p6). Now profiteering is a dirty wordand John DArcy, NPA director, hasstrongly defended the fee structure asbeing necessary to reflect the depthof professional input required by eachsale. He is correct and the publicdeserves this level ofpharmaceutical involvement. ButLevonelle-2 must not be allowed tobecome our Trojan horse. Sales protocols for medicines arenotoriously difficult to police, asevidenced by the succession of mediacovert investigations claiming to havefound weaknesses in the system. But Levonelle-2 is not a medicinewhere any relaxation of protocols canbe allowed. All community pharmacists mustconscientiously apply therecommendations to avoid thepossibility of covert investigationsexposing pharmaceutical control as asham
Size: 1086px × 2300px
Photo credit: © Reading Room 2020 / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: ., bookcentury1800, bookdecade185, booksubjectpharmacy, bookyear1859
